Featured Story BioCentury & Getty ImagesBIO: Two heads are better than one

The search for new leadership at BIO presents its board with generational opportunity to redefine the organization to ensure its relevance in a time of tumultuous political, technological and cultural ...

Featured Story z_wei /  iStock / Getty ImagesLong-term data help two drugs sway ICER in drug price report

An analysis by the Institute for Clinical and Economic Review of price increases for some of the costliest drugs in the U.S. has found that seven of nine were not supported by new clinical evidence, ...

Featured Story ULTRAMARINFOTO/ISTOCK/GETTY IMAGETime to fulfill China’s promise of IP reform

Two years ago, on Oct. 8, 2017, the top bodies of the Chinese Communist Party and the Chinese government created a pathway to IP reform that promised to propel the nation into the global innovation ...

Product Development OstapenkoOlena / iStock / Getty ImagesUCB adding Ra’s rare immunology assets in $2.5B takeout

UCB is looking to build its rare disease immunology franchise through its proposed $2.5 billion acquisition of Ra Pharmaceuticals -- a price that more than doubles the biotech’s valuation. The deal ...

Emerging Company Profile BioCentury & Getty ImagesGene editing vets launch Korro to convert RNA bases

A trio of gene editing industry veterans have teamed up to launch Korro Bio as their second company developing antisense-based therapies in less than a year. Korro is creating a new CRISPR-independent ...

Commentary ULTRAMARINFOTO/ISTOCK/GETTY IMAGE兑现中国知识产权改进承诺的时机已至

Publisher's note: the English language version of this article may be found here . 两年前的今天,2017年10月8日,中共中央和国务院的最高机构制定了知识产权改革的路线,下决心推动中国进入全球医药创新的生态系统。可惜这一宏伟规划尚未付诸实施。 ...

Finance BioCentury & Getty ImagesVir’s aftermarket weakness adds to skittishness for IPO queue

The tepid performances of two high-profile IPOs late in the week added to a widening body of evidence that investors’ demand for new biotech listings has begun to weaken, despite a long queue of ...

Finance BioCentury & Getty ImagesBeyond diabetes: T1D Fund’s new remit broadens venture base

The JDRF T1D Fund’s investment in ImmunoMolecular Therapeutics this week is the latest example of how the venture philanthropy fund is leveraging new insights around autoimmune biology and the fund’s ...

BioCentury ISSN 1097-7201